Both anti-IL-6R antibodies tocilizumab and sarilumab received black box warnings regarding the risks of serious infections for patients with pulmonary diseases, issued by the U.S. Food and Drug Administration (Food and Drug Administration, 2010; Food and Drug Administration, 2018). Here, IL6R is linked to infection.